Abstract
Background: Ursolic acid, a bioactive pentacyclic triterpenoid had been evaluated for its interaction with the neurological targets associated with antidepressant drugs. Current study was to mechanistically analyze the probable site of action for ursolic acid on the target proteins.
Methods: Ursolic acid has been docked with monoamine oxidase isoforms: MAO-A and MAO-B, LeuT (homologue of SERT, NET, DAT) and Human C-terminal CAP1 using GRIP docking methodology.
Results: Results revealed its non-selective antidepressant action with strong binding affinity towards LeuT and MAO-A proteins, which was found to be comparable with the reference ligands like chlorgyline, clomipramine, sertraline and deprenyl/selegiline.
Conclusion: Significant binding affinity of ursolic acid was seen with MAO-A, which indicated its potential role in other neurological disorders, for example, Alzheimer's disease and Parkinson disease besides depression.
Keywords: Ursolic acid, MAO-A inhibitor, MAO-B inhibitor, adenylyl cylase inhibitor, LeuT inhibitor, docking studies.
Graphical Abstract
Current Neuropharmacology
Title:In Silico Studies Revealed Multiple Neurological Targets for the Antidepressant Molecule Ursolic Acid
Volume: 15 Issue: 8
Author(s): Rajeev K. Singla, Luciana Scotti and Ashok K. Dubey*
Affiliation:
- Division of Biological Sciences and Engineering, Netaji Subhas Institute of Technology, Sector-3, Dwarka, New Delhi, 110078,India
Keywords: Ursolic acid, MAO-A inhibitor, MAO-B inhibitor, adenylyl cylase inhibitor, LeuT inhibitor, docking studies.
Abstract: Background: Ursolic acid, a bioactive pentacyclic triterpenoid had been evaluated for its interaction with the neurological targets associated with antidepressant drugs. Current study was to mechanistically analyze the probable site of action for ursolic acid on the target proteins.
Methods: Ursolic acid has been docked with monoamine oxidase isoforms: MAO-A and MAO-B, LeuT (homologue of SERT, NET, DAT) and Human C-terminal CAP1 using GRIP docking methodology.
Results: Results revealed its non-selective antidepressant action with strong binding affinity towards LeuT and MAO-A proteins, which was found to be comparable with the reference ligands like chlorgyline, clomipramine, sertraline and deprenyl/selegiline.
Conclusion: Significant binding affinity of ursolic acid was seen with MAO-A, which indicated its potential role in other neurological disorders, for example, Alzheimer's disease and Parkinson disease besides depression.
Export Options
About this article
Cite this article as:
Singla K. Rajeev, Scotti Luciana and Dubey K. Ashok*, In Silico Studies Revealed Multiple Neurological Targets for the Antidepressant Molecule Ursolic Acid, Current Neuropharmacology 2017; 15 (8) . https://dx.doi.org/10.2174/1570159X14666161229115508
DOI https://dx.doi.org/10.2174/1570159X14666161229115508 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Magnetic Resonance Elastography
Current Medical Imaging Role of Copper in Angiogenesis and Its Medicinal Implications
Current Medicinal Chemistry Recent Trends of Chalcones Potentialities as Antiproliferative and Antiresistance Agents
Anti-Cancer Agents in Medicinal Chemistry Double Strand Break Repair Activities of p53 as Potential Tumor Suppressor Function Counteracting Mammary Tumor Development
Current Women`s Health Reviews Growth Factor Signaling and Resistance to Cancer Chemotherapy
Current Topics in Medicinal Chemistry Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer
Current Medicinal Chemistry Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes
Current Drug Targets Diagnosis, Pathogenesis and Therapeutic Targets in Amyotrophic Lateral Sclerosis
CNS & Neurological Disorders - Drug Targets Novel Monocyte Biomarkers of Atherogenic Conditions
Current Pharmaceutical Design The Influence of Macrophages and the Tumor Microenvironment on Natural Killer Cells
Current Molecular Medicine Synthesis and Evaluation of Anticancer Activity of 5-Ylidene-4- Aminothiazol-2(5H)-one Derivatives
Medicinal Chemistry Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Thermal [3+2] Cycloaddition Reaction of N-Acyliminophenanthridinium Betaine with Allenoates: Facile Access to Phenanthridine-fused Tetracyclic Heterocycles
Letters in Organic Chemistry Nanotechnologies in Agriculture and Food - an Overview of Different Fields of Application, Risk Assessment and Public Perception
Recent Patents on Food, Nutrition & Agriculture Alteration of Ceramide 1-O-Functionalization as a Promising Approach for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Microarray: An Approach for Current Drug Targets
Current Drug Metabolism Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Targeting Nanoparticles as Drug Delivery Systems for Cancer Treatment
Current Nanoscience Shaping Tumor Microenvironment for Improving Nanoparticle Delivery
Current Drug Metabolism